| Security Name | Ticker | % of Net Assets |
|---|---|---|
| ABBVIE INC | ABBV | 7.85% |
| AMGEN INC. | AMGN | 5.66% |
| GILEAD SCIENCES, INC. | GILD | 4.81% |
| VERTEX PHARMACEUTICALS | VRTX | 4.17% |
| REGENERON PHARMACEUTICALS | REGN | 3.59% |
| ALNYLAM PHARMACEUTICALS | ALNY | 2.95% |
| INSMED INC | INSM | 2.87% |
| CORTEVA INC | CTVA | 2.34% |
| NATERA INC | NTRA | 2.14% |
| ASTRAZENECA PLC ADR | AZN | 2.09% |
| BEONE MEDICINES LTD-ADR | BGNE | 1.98% |
| BIOGEN IDEC, INC. | BIIB | 1.93% |
| ILLUMINA INC | ILMN | 1.75% |
| ROYALTY PHARMA PLC- CL A | RPRX | 1.73% |
| INCYTE CORP | INCY | 1.73% |
| GUARDANT HEALTH INC | GH | 1.69% |
| JAZZ PHARMACEUTICALS PLC | JAZZ | 1.59% |
| AVIDITY BIOSCIENCES INC | RNA | 1.57% |
| REVOLUTION MEDICINES INC | RVMD | 1.51% |
| EXACT SCIENCES | EXAS | 1.46% |
| ARGENX SE - ADR | ARGX | 1.46% |
| BRIDGEBIO PHARMA INC | BBIO | 1.46% |
| NEUROCRINE BIOSCIENCES IN | NBIX | 1.43% |
| VIATRIS INC | VTRS | 1.39% |
| IONIS PHARMACEUTICALS, IN | IONS | 1.38% |
| UNITED THERAPEUTICS CORP | UTHR | 1.36% |
| ROIVANT SCIENCES LTD | ROIV | 1.32% |
| EXELIXIS, INC. | EXEL | 1.30% |
| BIOMARIN PHARMACEUTICAL | BMRN | 1.20% |
| CYTOKINETICS INC | CYTK | 1.19% |
| VAXCYTE INC | PCVX | 1.13% |
| MODERNA INC | MRNA | 1.08% |
| ALKERMES PLC | ALKS | 1.04% |
| HALOZYME THERAPEUTICS INC | HALO | 1.03% |
| PROTAGONIST THER | PTGX | 1.02% |
| PTC THERAPEUTICS | PTCT | 1.01% |
| ARROWHEAD PHARMACEUTICALS | ARWR | 1.01% |
| AXSOME THERAPEUT | AXSM | 1.01% |
| BIONTECH SE-ADR | BNTX | 0.98% |
| NUVALENT INC-A | NUVL | 0.96% |
| CRISPR THERAPEUTICS AG | CRSP | 0.96% |
| VIKING THERAPEUTICS INC | VKTX | 0.96% |
| CRINETICS PHARMACEUTICALS | CRNX | 0.89% |
| AKERO THERAPEUTICS INC | AKRO | 0.85% |
| LEGEND BIOTECH CORP-ADR | LEGN | 0.83% |
| TG THERAPEUTICS | TGTX | 0.77% |
| MEDPACE HOLDINGS | MEDP | 0.77% |
| DYNE THERAPEUTICS INC | DYN | 0.76% |
| IDEAYA BIOSCIENCES INC | IDYA | 0.74% |
| VERACYTE INC | VCYT | 0.73% |
| ADMA BIOLOGICS INC | ADMA | 0.70% |
| AMICUS THERAPEUTICS INC | FOLD | 0.70% |
| ULTRAGENYX PHARM | RARE | 0.67% |
| ACADIA PHARMACEUTICALS IN | ACAD | 0.66% |
| ARCELLX INC | ACLX | 0.63% |
| MADRIGAL PHARMAC | MDGL | 0.62% |
| AGIOS PHARMACEUT | AGIO | 0.61% |
| IMMUNOVANT INC | IMVT | 0.60% |
| DENALI THERAPEUT | DNLI | 0.58% |
| BEAM THERAPEUTICS INC | BEAM | 0.52% |
| ASCENDIS PHA-ADR | ASND | 0.52% |
| APELLIS PHARMACE | APLS | 0.51% |
| CELLDEX THERAPEUTICS INC | CLDX | 0.51% |
| SUMMIT THERAPEUTICS INC | SMMT | 0.50% |
| SAREPTA THERAPEU | SRPT | 0.47% |
| TWIST BIOSCIENCE CORP | TWST | 0.47% |
| KRYSTAL BIOTECH INC | KRYS | 0.47% |
| DYNAVAX TECHNOLOGY | DVAX | 0.46% |
| RECURSION PHARMACEUTICALS | RXRX | 0.44% |
| NOVAVAX INC | NVAX | 0.35% |
| SOLENO THERAPEUTICS INC | SLNO | 0.33% |
| INTELLIA THERAPE | NTLA | 0.31% |
| IOVANCE BIOTHERAPEUTICS | IOVA | 0.20% |
| Other (Cash, derivatives and other liabilities) | 0.74% | |
| Total: | ||
Read a prospectus and summary prospectus (if available) carefully before investing. It contains the investment objective, risks charges, expenses and the other information, which should be considered carefully before investing. To obtain a prospectus and summary prospectus (if available) click here or call 800.820.0888.
Investing involves risk, including the possible loss of principal.
Guggenheim Investments represents the following affiliated investment management businesses of Guggenheim Partners, LLC: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Wealth Solutions, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Private Investments, LLC.
© 2025 Guggenheim Investments. All Rights Reserved.
Research our firm with FINRA Broker Check.
• Not FDIC Insured • No Bank Guarantee • May Lose Value
This website is directed to and intended for use by citizens or residents of the United States of America only. The material provided on this website is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation. Investing involves risk, including the possible loss of principal.